Status:
TERMINATED
Effect of Pegvisomant on GH/IGF-I Relationship in GHD
Lead Sponsor:
The Christie NHS Foundation Trust
Conditions:
Severe Adult Growth Hormone Deficiency
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
Approximately 50% of middle-aged patients with severe AGHD have a normal age-related serum IGF-I. It remains unclear if in these individuals serum IGF-I is GH dependent or independent. This study comp...
Detailed Description
There is an increasing reliance on serum insulin-like factor-I (IGF-I) in the management of disturbances of the growth hormone (GH) axis. IGF-I is predominantly, but not exclusively, regulated by GH s...
Eligibility Criteria
Inclusion
- Over 18 years of age
- Confirmed severe AGHD
- GH response \<9 mU/l (preferably \<4) to insulin-induced hypoglycaemia or glucagon stimulation test plus (These tests will have taken place as part of routine management).
- Full, stable pituitary replacement therapy
- Willing to provide informed consent
Exclusion
- Unwilling to provide written consent
- Current GH therapy
- Pharmacological doses of glucocorticoids
- Any acute illness
Key Trial Info
Start Date :
December 1 2004
Trial Type :
INTERVENTIONAL
End Date :
July 1 2005
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00468624
Start Date
December 1 2004
End Date
July 1 2005
Last Update
May 3 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Christie Hospital NHS Trust
Manchester, United Kingdom, M20 4BX